Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Extended release niacin/laropiprant demonstrates efficacy in dyslipidemia

Sep. 4, 2007

Abbott and AstraZeneca to advance ABT-335 and Crestor combination

Sep. 4, 2007

Amgen describes new 11beta-HSD1 inhibitors with potential use in treating type 2 diabetes

Sep. 4, 2007

Positive phase II trial results for Histalean in obese women under 50

Sep. 3, 2007

Pharming reports positive interim results from phase III trial of Rhucin for HAE

Aug. 31, 2007

Somatuline Depot approved in U.S. for acromegaly

Aug. 31, 2007

Discovery of xanthine-based DPP-IV inhibitor BI-1356 discussed at ACS meeting

Aug. 31, 2007

NDA for Merck & Co.'s lipid-modifier, Cordaptive, accepted for review

Aug. 31, 2007

Novel compounds with chaperone activity may be useful in Gaucher's disease

Aug. 31, 2007

Ambrilia reports update on clinical trials of prolonged release octreotide

Aug. 31, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...